Nuvation Bio Inc. (NYSE:NUVB) is one of the best biotech penny stocks to buy right now. In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB), setting a price target of $6.00.
A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory.
On June 11, Nuvation Bio Inc. announced the US Food and Drug Administration’s (FDA) approval of IBTROZI (taletrectinib) to treat adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) that addresses some of the outstanding challenges associated with the treatment of ROS1+ NSCLC.
The product is generally well tolerated and exhibits a high response rate with durable benefit and intracranial activity, offering a new treatment option for advanced ROS1+ NSCLC.
Nuvation Bio is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology.
It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC).
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
